Elicio Therapeutics (ELTX) Cash & Equivalents (2020 - 2026)

Elicio Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 18.54% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (down 18.54% YoY), and the FY2025 full-year result was $18.6 million, up 5.36% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $14.9 million, down from $18.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $73.0 million in Q1 2022, with the low at $598000.0 in Q2 2022.
• Historically, Cash & Equivalents has averaged $17.2 million across 5 years, with a median of $14.9 million in 2026.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 99.49% — and 2023, when it soared 3525.75%.
• Elicio Therapeutics' Cash & Equivalents stood at $6.2 million in 2022, then soared by 109.45% to $12.9 million in 2023, then soared by 36.64% to $17.6 million in 2024, then advanced by 5.36% to $18.6 million in 2025, then slipped by 19.47% to $14.9 million in 2026.
• The last three Cash & Equivalents figures came in at $14.9 million (Q1 2026), $18.6 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.